Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Medidur phase III trial recommended to continue

March 22, 2006

Neurotech reports promising results of phase I NT-501 safety trial

March 15, 2006

New antiglaucoma agents disclosed in recent patents

March 14, 2006

Enrollment completed in phase I study of AdPEDF gene therapy

March 10, 2006

Lucentis submitted for European approval for wet AMD

March 6, 2006

Evizon 40 mg safe and active in stabilizing vision in wet AMD

March 6, 2006

NicOx signs new ophthalmology agreement with Pfizer

March 6, 2006

Alcon withdraws European submission for Retaane

March 3, 2006

Lucentis BLA for wet AMD granted priority review

March 3, 2006

Recent patents disclose novel ophthalmic drugs

Feb. 28, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...